Elvitegravir (GS-9137)|2mg|K1323-上海高创化学科技有限公司

SKU:K1323		M. Wt:447.88
Formula:C23H23ClFNO5		Solubility:No
Purity:>99%		Storage:2 years at -20 degrees centigrade
CAS No.:697761-98-1		Synonyms:N/A
Chemical NameN/A

Description	Elvitegravir (GS-9137)
Targets	HIV-1 IIIB	HIV-2 EHO	HIV-2 ROD
IC50	0.7 nM	2.8 nM	1.4 nM
In vitro	Elvitegravir (EVG, JTK-303/GS-9137) can inhibit HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM. Elvitegravir is predominantly metabolized via cytochrome P450 (CYP)3A4, along with minor pathways including glucuronidation via UGT1A1/3 and oxidative metabolism. Elvitegravir (EVG, JTK-303, GS-9137) currently being developed for the treatment of HIV-1 infection. Elvitegravir was more potent than raltegravir,a newly approved anti-AIDS drug. Elvitegravir can inhibit clinical HIV-2 isolates with IC50 of 0.7 nM while raltegravir inhibits those HIV-2 isolates with IC50 of 2.4 nM. Neither elvitegravir nor raltegravir could block disintegration. Elvitegravir (EVG) blocks the integration of HIV-1 cDNA through the inhibition of DNA strand transfer. Elvitegravir can inhibit the replication of HIV-1, including various subtypes and multiple-drug-resistant clinical isolates, and HIV-2 strains with a 50% effective concentration in the subnanomolar to nanomolar range. Clade-specific HIV-1 integrase polymorphisms do not reduce elvitegravir phenotypic susceptibility.
In vivo	Elvitegravir pharmacokinetic GMR was 6-7% higher following elvitegravir/r plus etravirine dosing versus elvitegravir/r. The coadministration of elvitegravir with the protease inhibitor ritonavir (a substantial CYP3A4 inhibitor) results in significantly enhanced bioavailability and a longer half-life than with elvitegravir alone, allowing for the once-daily dosing of elvitegravir.
Clinical Trials	N/A
Features	N/A

Description

Elvitegravir (GS-9137)

Targets

HIV-1 IIIB

HIV-2 EHO

HIV-2 ROD

IC50

0.7 nM

2.8 nM

1.4 nM

In vitro

Elvitegravir (EVG, JTK-303/GS-9137) can inhibit HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM. Elvitegravir is predominantly metabolized via cytochrome P450 (CYP)3A4, along with minor pathways including glucuronidation via UGT1A1/3 and oxidative metabolism. Elvitegravir (EVG, JTK-303, GS-9137) currently being developed for the treatment of HIV-1 infection. Elvitegravir was more potent than raltegravir,a newly approved anti-AIDS drug. Elvitegravir can inhibit clinical HIV-2 isolates with IC50 of 0.7 nM while raltegravir inhibits those HIV-2 isolates with IC50 of 2.4 nM. Neither elvitegravir nor raltegravir could block disintegration. Elvitegravir (EVG) blocks the integration of HIV-1 cDNA through the inhibition of DNA strand transfer. Elvitegravir can inhibit the replication of HIV-1, including various subtypes and multiple-drug-resistant clinical isolates, and HIV-2 strains with a 50% effective concentration in the subnanomolar to nanomolar range. Clade-specific HIV-1 integrase polymorphisms do not reduce elvitegravir phenotypic susceptibility.

In vivo

Elvitegravir pharmacokinetic GMR was 6-7% higher following elvitegravir/r plus etravirine dosing versus elvitegravir/r. The coadministration of elvitegravir with the protease inhibitor ritonavir (a substantial CYP3A4 inhibitor) results in significantly enhanced bioavailability and a longer half-life than with elvitegravir alone, allowing for the once-daily dosing of elvitegravir.

Clinical Trials

N/A

Features

N/A

工商信息

企业名称

上海高创化学科技有限公司

企业信息已认证

企业类型

信用代码

310228001353263

成立日期

2010-06-05

注册资本

经营范围

从事化学科技、计算机领域内技术开发、技术咨询、技术服务,从事生物科技领域内技术开发、技术咨询,化学试剂、化工原料及产品(除危险化学品、监控化学品、烟花爆竹、民用爆炸物品、易制毒化学品),实验室设备(除医疗器械),仪器仪表,Ⅰ类医疗器械,金属制品,电子产品,机电产品销售。【依法须经批准的项目,经相关部门批准后方可开展经营活动】

Elvitegravir (GS-9137)由上海高创化学科技有限公司为您提供，货号K1323，规格：2mg，CAS号：697761-98-1，如您想了解更多关于Elvitegravir (GS-9137)价格、Elvitegravir (GS-9137)结构式、批发、用途等信息，欢迎咨询。除供应Elvitegravir (GS-9137)外，还可为您提供重组人半乳糖凝集素3/Human LGALS3 His、重组大鼠抵抗素(Rat Resistin)、热灭活胎牛血清（澳大利亚）等试剂，公司有专业的客户服务团队，是您值得信赖的合作伙伴，上海高创客户服务电话，售前、售后均可联系。